Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Current Alzheimer's disease (AD) drug development heavily relies on amyloid-targeting therapies.
• There is a growing consensus that targeting additional mechanisms is crucial for effective AD treatment.
• The EU/US CTAD Task Force convened to discuss alternative disease-modifying strategies for AD.

Purpose of the Study:

• To explore and propose alternative therapeutic strategies beyond amyloid targeting for Alzheimer's disease.
• To identify key areas for accelerating the development of novel AD treatments.
• To foster collaboration and refine clinical trial designs for AD therapies.

Main Methods:

• Discussion and consensus-building among experts at the EU/US CTAD Task Force meeting in December 2019.
• Review of emerging therapeutic targets including tau, neurotrophin receptors, antimicrobials, and innate immunity.
• Consideration of vascular, aging, and non-pharmacological interventions like lifestyle, photobiomodulation, and neurostimulation.

Main Results:

• Identification of multiple promising alternative therapeutic avenues for AD.
• Recognition of the need for a multi-faceted approach to AD treatment.
• Proposed strategy emphasizing increased partnerships, improved trial designs, and combination therapies.

Conclusions:

• Effective Alzheimer's disease treatment likely requires targeting multiple pathways beyond amyloid.
• Accelerating the development of alternative AD therapies necessitates strategic collaborations and innovative trial designs.
• Combination therapy approaches hold significant promise for future AD treatment strategies.